VG Life Sciences Inc. (VGLS)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 20.34 Thousand USD | -14.38% |
| 2022 | 23.76 Thousand USD | -97.96% |
| 2021 | 1.16 Million USD | -1.86% |
| 2020 | 1.18 Million USD | 3348.96% |
| 2019 | 34.4 Thousand USD | 0.0% |
| 2018 | 34.4 Thousand USD | 0.0% |
| 2017 | 34.4 Thousand USD | -94.21% |
| 2016 | 594.5 Thousand USD | 0.0% |
| 2014 | 4.14 Million USD | 6.04% |
| 2013 | 3.9 Million USD | 122747.68% |
| 2012 | 3180.87 USD | 0.0% |
| 2006 | 6.37 Million USD | 43.54% |
| 2005 | 4.44 Million USD | -40.94% |
| 2004 | 7.52 Million USD | 86.68% |
| 2003 | 4.02 Million USD | 232.03% |
| 2002 | 1.21 Million USD | 35.29% |
| 2001 | 897.01 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 2752.00 USD | -55.88% |
| 2024 Q1 | 6237.00 USD | 10.19% |
| 2023 Q1 | 4073.00 USD | -76.84% |
| 2023 Q2 | 8910.00 USD | 118.76% |
| 2023 Q4 | 5660.00 USD | 232.94% |
| 2023 Q3 | 1700.00 USD | -80.92% |
| 2023 FY | 20.34 Thousand USD | -14.38% |
| 2022 Q3 | 3923.00 USD | 0.0% |
| 2022 Q1 | 2250.00 USD | -35.71% |
| 2022 FY | 23.76 Thousand USD | -97.96% |
| 2022 Q4 | 17.58 Thousand USD | 348.3% |
| 2021 FY | 1.16 Million USD | -1.86% |
| 2021 Q4 | 3500.00 USD | -99.65% |
| 2021 Q3 | 1 Million USD | 520.59% |
| 2021 Q2 | 161.13 Thousand USD | 0.0% |
| 2020 FY | 1.18 Million USD | 3348.96% |
| 2019 FY | 34.4 Thousand USD | 0.0% |
| 2018 FY | 34.4 Thousand USD | 0.0% |
| 2017 FY | 34.4 Thousand USD | -94.21% |
| 2016 FY | 594.5 Thousand USD | 0.0% |
| 2015 Q3 | 644.44 Thousand USD | -12.83% |
| 2015 Q2 | 739.26 Thousand USD | -7.76% |
| 2015 Q1 | 801.48 Thousand USD | 48.02% |
| 2014 Q1 | 1.65 Million USD | -22.62% |
| 2014 Q2 | 1.15 Million USD | -30.27% |
| 2014 Q3 | 798.77 Thousand USD | -30.65% |
| 2014 FY | 4.14 Million USD | 6.04% |
| 2014 Q4 | 541.45 Thousand USD | -32.21% |
| 2013 Q2 | 398.58 Thousand USD | 19969.64% |
| 2013 Q3 | 853.63 Thousand USD | 114.17% |
| 2013 Q4 | 2.13 Million USD | 150.05% |
| 2013 Q1 | 1986.01 USD | 0.0% |
| 2013 FY | 3.9 Million USD | 122747.68% |
| 2012 FY | 3180.87 USD | 0.0% |
| 2007 Q1 | 540.62 Thousand USD | -32.54% |
| 2007 Q2 | 870.55 Thousand USD | 61.03% |
| 2007 Q3 | 880.48 Thousand USD | 1.14% |
| 2006 Q2 | 1.72 Million USD | -47.49% |
| 2006 FY | 6.37 Million USD | 43.54% |
| 2006 Q4 | 801.45 Thousand USD | 48.35% |
| 2006 Q3 | 540.25 Thousand USD | -68.7% |
| 2006 Q1 | 3.28 Million USD | 108.15% |
| 2005 Q1 | 1.13 Million USD | -19.44% |
| 2005 Q3 | 606.99 Thousand USD | -40.91% |
| 2005 Q2 | 1.02 Million USD | -9.32% |
| 2005 Q4 | 1.57 Million USD | 160.18% |
| 2005 FY | 4.44 Million USD | -40.94% |
| 2004 FY | 7.52 Million USD | 86.68% |
| 2004 Q1 | 1.65 Million USD | -13.97% |
| 2004 Q2 | 3.5 Million USD | 112.43% |
| 2004 Q3 | 957.03 Thousand USD | -72.71% |
| 2004 Q4 | 1.4 Million USD | 46.93% |
| 2003 FY | 4.02 Million USD | 232.03% |
| 2003 Q4 | 1.91 Million USD | 168.1% |
| 2003 Q1 | 155.14 Thousand USD | -7.07% |
| 2003 Q3 | 715.86 Thousand USD | -49.45% |
| 2003 Q2 | 1.41 Million USD | 812.75% |
| 2002 Q3 | 743.24 Thousand USD | 417.76% |
| 2002 Q2 | 143.55 Thousand USD | -10.17% |
| 2002 Q1 | 159.8 Thousand USD | -76.24% |
| 2002 FY | 1.21 Million USD | 35.29% |
| 2002 Q4 | 166.94 Thousand USD | -77.54% |
| 2001 FY | 897.01 Thousand USD | 0.0% |
| 2001 Q4 | 672.71 Thousand USD | 21378.86% |
| 2001 Q3 | 3132.00 USD | -98.93% |
| 2001 Q1 | 33.65 Thousand USD | -9.11% |
| 2001 Q2 | 292.19 Thousand USD | 768.09% |
| 2000 Q4 | 37.03 Thousand USD | -38.0% |
| 2000 Q3 | 59.72 Thousand USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | 98.477% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 99.597% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 99.931% |
| Nascent Biotech, Inc. | 2.22 Million USD | 99.088% |
| Rebus Holdings, Inc. | 664 Thousand USD | 96.936% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 99.945% |
| Qrons Inc. | 643.67 Thousand USD | 96.84% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | 94.778% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 99.965% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | 95.104% |
| Skye Bioscience, Inc. | 13.54 Million USD | 99.85% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 99.977% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 99.586% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | 92.227% |
| SQZ Biotechnologies Company | 85.61 Million USD | 99.976% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | 99.302% |
| Propanc Biopharma, Inc. | 1.5 Million USD | 98.646% |
| Mesoblast Limited | 5.9 Million USD | 99.655% |
| Marizyme, Inc. | 19.23 Million USD | 99.894% |
| Genus plc | 147.7 Million USD | 99.986% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 99.768% |
| Pharming Group N.V. | 225.49 Million USD | 99.991% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | 99.007% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | 98.484% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 99.756% |
| ContraFect Corporation | 56.88 Million USD | 99.964% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 99.539% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | 98.624% |
| IMV Inc. | 37.7 Million USD | 99.946% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | 99.271% |
| MultiCell Technologies, Inc. | 567.42 USD | -3485.175% |
| ONE Bio Corp. | 6.44 Million USD | 99.684% |
| Accustem Sciences Inc. | 3.74 Million USD | 99.457% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 99.976% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | 96.176% |
| Q BioMed Inc. | 3.43 Million USD | 99.408% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 99.918% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | 99.226% |
| Biomind Labs Inc. | 994.18 Thousand USD | 97.954% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 99.98% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | 98.844% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 99.697% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | 98.909% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 181.372% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 99.873% |
| Curative Biotechnology, Inc. | 1.83 Million USD | 98.891% |
| GB Sciences, Inc. | 1.42 Million USD | 98.568% |
| Alpha Cognition Inc. | 9.7 Million USD | 99.79% |
| HST Global, Inc. | 140.9 Thousand USD | 85.563% |
| CSL Limited | 3.44 Billion USD | 99.999% |
| Wesana Health Holdings Inc. | 1.12 Million USD | 98.192% |
| Halberd Corporation | 74.84 Thousand USD | 72.819% |
| Enzolytics Inc. | 2.17 Million USD | 99.067% |
| Agentix Corp. | 1.37 Million USD | 98.517% |
| Resverlogix Corp. | 12.71 Million USD | 99.84% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | 99.443% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.999% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | 98.051% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | 99.154% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | 98.712% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | 99.403% |
| AVAX Technologies, Inc. | 7.31 Million USD | 99.722% |
| Zenith Capital Corp. | 8.94 Million USD | 99.773% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.998% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -16.773% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | 99.171% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | 88.139% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | 98.941% |
| Kadimastem Ltd | 2.41 Million USD | 99.156% |
| Helix BioMedix, Inc. | 1.97 Million USD | 98.968% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 99.813% |
| BioStem Technologies, Inc. | 22.97 Million USD | 99.911% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | 88.791% |
| LadRx Corporation | 3.81 Million USD | 99.466% |
| Cell Source, Inc. | 4.32 Million USD | 99.53% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | 97.797% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | 97.797% |
| NovAccess Global Inc. | 2.46 Million USD | 99.175% |
| Affymax, Inc. | 39.38 Million USD | 99.948% |
| Itoco Inc. | 919.14 Thousand USD | 97.787% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 99.52% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | 98.182% |
| Mobile Lads Corp. | 554.54 Thousand USD | 96.332% |
| CytoDyn Inc. | 18.05 Million USD | 99.887% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | 19.174% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | 90.756% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | 98.567% |
| SYBLEU INC | 160.87 Thousand USD | 87.355% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | 98.88% |
| International Stem Cell Corporation | 5.27 Million USD | 99.614% |
| Bioxytran, Inc. | 3.82 Million USD | 99.467% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | 61.356% |
| Cardax, Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 99.944% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | 98.743% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | 97.235% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | 99.346% |
| Neutra Corp. | 243.82 Thousand USD | 91.657% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 99.883% |
| PureTech Health plc | 144.59 Million USD | 99.986% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 99.901% |
| IXICO plc | 4.7 Million USD | 99.568% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 99.769% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 99.983% |
| CSL Limited | 3.89 Billion USD | 99.999% |
| Cellectis S.A. | 97.32 Million USD | 99.979% |